{
  "id": 20888756,
  "title": "Ebola vaccine trials launches amid security concerns",
  "url": "https://urgent.news/2026/11/20/ebola-vaccine-trials-launches-amid-security-concerns",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-20T11:13:58.000Z",
  "source": {
    "name": "Semafor",
    "slug": "semafor",
    "url": "https://www.semafor.com/article/11/20/2026/ebola-vaccine-trials-launches-amid-security-concerns"
  },
  "original_language": "en",
  "account": "Large-scale trials of three Ebola vaccines against the Bundibugyo strain are set to launch in the heart of the Democratic Republic of Congo's outbreak, potentially yielding a breakthrough early next year, according to a global vaccine organization's leader. The Bundibugyo strain, for which no proven vaccine exists, has caused over 5,500 deaths since May's outbreak declaration, now the second-largest recorded. Most cases, exceeding 11,000, are concentrated in the conflict-ridden eastern part of the country. The Tumaini trial, aiming to test vaccine candidates, will involve at least 1,000 people to assess safety and efficacy. An Ervebo trial, developed by Merck for the more common Zaire strain, commenced on October 23. Two other vaccines, designed to target the Bundibugyo strain, will join the trial shortly and include one developed by Oxford University scientists and another by Moderna, utilizing COVID-19 vaccine technology. Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations, believes an early next-year result is feasible. However, even if data proves a vaccination's safety and effectiveness, Congolese and global health regulators will review it before authorizing emergency use, which could delay deployment. Emanuele Capobianco, GAVI's global health security director, anticipates potential vaccine deployment by mid-2027 if trials succeed. The Ervebo trial began in Ituri, the most affected province, but the trial's testing area may expand to include other provinces, including North Kivu. Conflict and misinformation in eastern Congo, including rebel groups and community distrust, hinder outbreak control efforts. Hatchett and Capobianco emphasize insecurity as a major obstacle to vaccine trials, highlighting the need for healthcare workers, religious leaders, and community authorities' involvement. The World Health Organization reports 400 to 500 new cases weekly, with delayed payments to frontline health workers slowing the response. The Africa Centres for Disease Control and Prevention's director-general warns the outbreak is still not under control, six months after its declaration. US pharmaceutical company Gilead has entered royalty-free licensing agreements with three generic manufacturers for potential future access to an antiviral being trialed for Bundibugyo strain exposure.",
  "summary": "Insecurity in eastern DR Congo is likely to make the trial process challenging, warn health experts.",
  "key_points": [
    "Three Ebola vaccines, including one by Merck, launch Tumaini trial in DRC",
    "Bundibugyo strain, causing over 5,500 deaths, has no proven vaccine",
    "Insecurity and misinformation hinder outbreak control efforts in eastern Congo"
  ],
  "editors_take": "Testing new vaccine candidates in conflict-ridden provinces forces researchers to navigate deep community distrust and physical insecurity to address a deadly outbreak that currently lacks a proven preventative measure.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}